A European Medicines Agency (EMA) committee on Friday recommended adding heavy menstrual bleeding to the list of side effects of mRNA COVID-19 shots manufactured by Pfizer/BioNTech and Moderna.
WeLoveTrump reported OVER A YEAR AGO about the effects of the experimental shots on the menstrual cycle of women.
The Jab May Have Some REALLY Concerning Side Effects For Women
WeLoveTrump also reported on a major Norwegian survey first published in December 2021 that found an increased incidence of menstrual disorders in young women after receiving the experimental injection.
Norwegian Survey Finds COVID-19 Jabs Increase Incidence of Menstrual Disorders in Young Women
Women who received the COVID-19 shot have reported spotting in between their cycles, shortened cycles, and lengthened cycles.
However, their concerns were dismissed and anyone who spoke up was deemed a "conspiracy theorist."
EU regulator recommends adding heavy periods to side effects of mRNA COVID shots https://t.co/aZ9x76yspl pic.twitter.com/e0RaX7el2m
— Reuters (@Reuters) October 28, 2022
The Gateway Pundit reported:
Earlier this year, the EMA’s risk assessment committee announced that it would review reports of menstruation irregularities after thousands of women reported changes to their monthly cycle after getting the COVID vaccine.
“After reviewing the available evidence, the PRAC decided to request an in-depth evaluation of all available data, including reports from spontaneous reporting systems, clinical trials, and the published literature,” according to the news release.
“At this stage, it is not yet clear whether there is a causal link between the COVID-19 vaccines and the reports of heavy periods or amenorrhea. There is also no evidence to suggest that COVID-19 vaccines affect fertility,” the agency said.
Now, the regulatory body recommended including “heavy menstrual bleeding” as an adverse effect on the list of product warnings and precautions.
Review the EMA statement below:
The PRAC has recommended that heavy menstrual bleeding should be added to the product information as a side effect of unknown frequency of the mRNA COVID-19 vaccines Comirnaty and Spikevax.
Heavy menstrual bleeding (heavy periods) may be defined as bleeding characterised by an increased volume and/or duration which interferes with the person’s physical, social, emotional and material quality of life. Cases of heavy menstrual bleeding have been reported after the first, second and booster doses of Comirnaty and Spikevax.
The PRAC finalised the assessment of this safety signal after reviewing the available data, including cases reported during clinical trials, cases spontaneously reported in Eudravigilance and findings from the medical literature.
After reviewing the data, the Committee concluded that there is at least a reasonable possibility that the occurrence of heavy menstrual bleeding is causally associated with these vaccines and therefore recommended the update of the product information.
The available data reviewed involved mostly cases which appeared to be non-serious and temporary in nature.
Menstrual disorders in general are quite common and they can occur for a wide range of reasons. This includes some underlying medical conditions. Any person who experiences postmenopausal bleeding or is concerned about a change in menstruation should consult their doctor.
There is no evidence to suggest the menstrual disorders experienced by some people have any impact on reproduction and fertility. Available data provides reassurance about the use of mRNA COVID-19 vaccines before and during pregnancy. A review carried out by EMA’s Emergency Task Force showed that mRNA COVID-19 vaccines do not cause pregnancy complications for expectant mothers and their babies, and they are as effective at reducing the risk of hospitalisation and deaths in pregnant people as they are in non-pregnant people.
The Committee reiterates that the totality of data available confirms that the benefits of these vaccines greatly outweigh the risks.
Healthcare professionals and patients are encouraged to continue to report cases of heavy menstrual bleeding to their national authorities.
The PRAC will continue to monitor for cases of this condition and will communicate further if new recommendations are warranted.
Join the conversation!
Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!